



NANOLOGICA




NANOLOGICA

BETTER AND CHEAPER MEDICINE THROUGH NANOPOROUS SILICA

Nanologica develops nanoporous silica for drug delivery formulation. Nanologica's proprietary NLAB Silica™ particles solves problems in pharmaceutical formulations by improving solubility, enhancing bioavailability and protecting APIs from degradation.


Benefits of NLAB Silica™

- ENHANCING DISSOLUTION KINETICS OF POORLY SOLUBLE COMPOUNDS
- CONTROLLING RELEASE KINETICS
- IMPROVING BIOAVAILABILITY
- STABILIZING AMORPHOUS FORM
- IMPROVING HANDLING OF APIs
- APPLICABLE FOR A BROAD RANGE OF APIs



Reformulation of the HIV drug Atazanavir (ATV) using NLAB Silica™ for improved bioavailability in vivo.

NLAB Silica™



- Nanoporous amorphous silica
- GRAS approved excipient
- Tuneable particle and pore size
- High loading up to 50%
- Free-flowing powder

Business model

- Licensing agreements/ technology transfer
- Feasibility studies
- Fee for service contracts
- Development of own assets



Contact

Professor Adam Feiler | Chief Technical Officer
adam.feiler@nanologica.com

Ms. Kia Bengtsson | Director Clinical Development
kia.bengtsson@nanologica.com